A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors
Sign Up to like & getrecommendations! Published in 2017 at "BMC Cancer"
DOI: 10.1186/s12885-017-3143-6
Abstract: BackgroundThe RAS/RAF/MEK/ERK pathway is constitutively activated in many cancers. Selumetinib (AZD6244, ARRY-142886) is an oral, potent and highly selective, allosteric MEK1/2 inhibitor with a short half-life that has shown clinical activity as monotherapy in phase… read more here.
Keywords: combination; selumetinib plus; solid tumors; advanced solid ... See more keywords